



17205-Review

Quotes Excluded
Bibliography Excluded12%
SIMILAR

8

Name of journal: World Journal of Hepatology

ESPS Manuscript NO: 17205

Columns: Editorial

Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure

Marcello Maida, Massimo Iavarone, Maurizio Raineri, Calogero Cammà, Giuseppe Cabibbo

Abstract

2

Hepatocellular carcinoma (HCC) is the main cause of death in patients with cirrhosis, with an increasing incidence worldwide. Sorafenib is the choice therapy for advanced HCC.

Over time several randomized phase III trials have been performed testing sunitinib, brivanib, linifanib and other molecules in head-to-head comparison with Sorafenib as first-line treatment for advanced-stage HCC, but none of these has so far been registered in this setting.

6

Moreover, another feared vacuum arises from the absence of molecules registered as

Match Overview

1

CrossCheck 52 words

Iavarone, Massimo, Giuseppe Cabibbo, Marco Biolato, Cristina Della Corte, Marcello Maida, Marco Barbàra, Michele

2%

2

CrossCheck 41 words

Luigi Bolondi. "From liver cirrhosis to HCC", Internal and Emergency Medicine, 10/2011

1%

3

CrossCheck 39 words

Giuseppe Cabibbo. "Update on new approaches in the management of hepatocellular carcinoma", Hepatic Medicine

1%

4

CrossCheck 38 words

Cammà, Calogero, Giuseppe Cabibbo, Salvatore Petta, Marco Enea, Massimo Iavarone, Antonio Grieco, Antonio Ga

1%

5

CrossCheck 34 words

Hsu, Chiun, Ying-Chun Shen, and Ann-Lii Cheng. "Antiangiogenic strategies for the treatment of hepatocellular carcinoma"

1%

6

CrossCheck 31 words

Chan, Stephen L, and Tony Mok. "Targeted therapy for hepatocellular carcinoma: current status and future direction"

1%

7

CrossCheck 21 words

Massimo Iavarone. "Field-practice study of sorafenib the

1%



SECOND LINE SYSTEMIC THERAPIES FOR HEPATOCELLULAR CAR



网页

新闻

图片

视频

更多 ▾

搜索工具

找到约 5,460,000 条结果 (用时 0.64 秒)

Google 学术: SECOND LINE SYSTEMIC THERAPIES FOR HEPATOCELLULAR CARCINOMA: REASONS FOR THE FAILURE

... endpoints of clinical trials in hepatocellular carcinoma - Llovet - 被引用次数: 995

... in patients with unresectable hepatocellular carcinoma ... - Llovet - 被引用次数: 2028

Second-line treatment of ovarian cancer - Markman - 被引用次数: 228

Hepatocellular carcinoma: reasons for phase III failure and ...

www.ncbi.nlm.nih.gov/pubmed/24589894 ▾ 翻译此页

作者: JM Llovet - 2014 - 被引用次数: 24 - 相关文章

2014年3月3日 - Hepatocellular carcinoma: reasons for phase III failure and novel ...

Sorafenib remains the only approved systemic drug for these patients. Molecular therapies targeting signaling cascades involved in ... erlotinib, and linifanib) or second-line (brivanib, everolimus) setting after sorafenib progression.

Prognosis of patients with advanced hepatocellular ...

www.ncbi.nlm.nih.gov/pubmed/24036008 ▾ 翻译此页

作者: YY Shao - 2014 - 被引用次数: 8 - 相关文章

2013年9月12日 - ... hepatocellular carcinoma who failed first-line systemic therapy. ...

especially those eligible for clinical trials of second-line therapy, is unclear.

[网页](#)[新闻](#)[图片](#)[视频](#)[购物](#)[更多 ▾](#)[搜索工具](#)

找到约 2,490,000 条结果 (用时 0.70 秒)

Google 学术: Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure

... endpoints of clinical trials in hepatocellular carcinoma - Llovet - 被引用次数: 1041

... in patients with unresectable hepatocellular carcinoma ... - Llovet - 被引用次数: 2131

... -line treatment of advanced hepatocellular carcinoma: ... - Santoro - 被引用次数: 180

Prognosis of patients with advanced hepatocellular ...

www.ncbi.nlm.nih.gov/pubmed/24036008 ▾ 翻译此页

作者: YY Shao - 2014 - 被引用次数: 12 - 相关文章

2013年9月12日 - ... hepatocellular carcinoma who failed first-line systemic therapy.

especially those eligible for clinical trials of second-line therapy, is unclear.

Systemic therapy for hepatocellular carcinoma (HCC): from ...

www.sciencedirect.com/science/article/.../S1110036213000897 ▾ 翻译此页

作者: O Abdel-Rahman - 2013 - 被引用次数: 24 - 相关文章

Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside ... common causes of cirrhosis have been identified as key risk factors for HCC. HCC patients who failed sorafenib) and further search for active second line ...

Systemic therapy in HCC: Lessons from brivanib

翻译此页

[网页](#)[新闻](#)[图片](#)[视频](#)[更多 ▾](#)[搜索工具](#)

找到约 263,000 条结果 (用时 0.58 秒)

Google 学术: Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure

... endpoints of clinical trials in hepatocellular carcinoma - Llovet - 被引用次数: 1042

... in patients with unresectable hepatocellular carcinoma ... - Llovet - 被引用次数: 2133

... -line treatment of advanced hepatocellular carcinoma: ... - Santoro - 被引用次数: 180

Prognosis of patients with advanced hepatocellular ...

www.ncbi.nlm.nih.gov/pubmed/24036008 ▾ 翻译此页

作者: YY Shao - 2014 - 被引用次数: 12 - 相关文章

2013年9月12日 - ... hepatocellular carcinoma who failed first-line systemic therapy. ... especially those eligible for clinical trials of second-line therapy, is unclear.

Systemic therapy for hepatocellular carcinoma (HCC): from ...

www.sciencedirect.com/science/article/.../S1110036213000897 ▾ 翻译此页

作者: O Abdel-Rahman - 2013 - 被引用次数: 24 - 相关文章

HCC is a complex disease associated with many risk factors and cofactors. First Line Systemic Treatment for Patients With Advanced Stage HCC (ESLC 1 study) ... HCC patients who failed sorafenib) and further search for active second line ...